Venturing further into BioHealth with Synergia

Novozymes is strengthening its BioHealth business with the acquisition of a majority stake in Synergia Life Sciences, a leading developer and manufacturer of vitamin K2 and probiotics.

Synergia Life Sciences Pte. Ltd. is a leading player in the field of vitamin K2-7 and spore-forming probiotics. Synergia has three production sites in India and services customers globally.

By acquiring Synergia Life Sciences, Novozymes accelerates its position in human health and functional foods, and bolsters its developing and manufacturing capabilities. The vitamin K2-7 portfolio is a strong complementary enabler to support growth in Novozymes’ BioHealth platform. Novozymes will continue to offer natural vitamin K2 to B2B customers under the MenaquinGold® ingredient brand.

Read the full press release here.

Would you like to connect with us? 

Let us know if you have questions regarding our solutions or if you want to learn more about Rethinking Tomorrow within Human Health.

If you don't hear from us within 48 hours, then we apologize for dropping the ball and would like to know immediately: 

Thanks for getting in contact, one of our team will respond to your query shortly.